Presidio pockets $26M in second VC round
San Francisco-based Presidio Pharmaceuticals, which is focused on developing therapies for chronic viral infections, has garnered $26 million in its second round. Panorama Capital led the round with Baker Brothers Investments, Bay City Capital, Ventures West Capital, Nexus Medical Partners and others participating.
"The proceeds of this financing will be used to advance two of our programs into human clinical studies, continue establishing alliances with outside partners, and expand our product portfolio through additional in-licensing transactions," said Dr. Omar K. Haffar, president and CEO of Presidio Pharmaceuticals.
- check out the release for more info
Related Article:
The top five VC deals of the first half of 2007. List
Be the first to comment
More stories about pharmaceuticals Venture Capital investments product portfolio Presidio Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
